NAD+ Injections: What the Research Actually Shows

"NAD+ injections" are sold as a faster, more convenient version of the IV drip — a small subcutaneous or intramuscular shot you can do at home, marketed for energy, focus, recovery, and anti-aging. The pitch is appealing and the search volume is enormous. But the right question, before you order a vial, is the unglamorous one: **what does the research actually show for injecting NAD+ — and how does that differ from the better-studied oral precursors?**

The honest answer is that NAD+ injections sit at the thin end of the evidence. They are largely a clinic- and telehealth-marketed product, not a trialed intervention. This page lays out what is genuinely known, where the marketing outruns the science, and what a course typically costs — so you can decide with clear eyes.

What a "NAD+ injection" actually is

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell. It shuttles electrons through the reactions that convert food into cellular energy, and it also fuels DNA-repair enzymes and the sirtuin proteins, which is why it sits at the center of metabolism and ageing biology ¹. NAD+ availability tends to fall with age — human-tissue work has documented age-associated declines in NAD+ alongside rising oxidative stress ² — and that decline is the entire rationale behind "NAD+ restoration."

A NAD+ injection takes that idea and delivers NAD+ itself — not a precursor — under the skin (subcutaneous) or into a muscle (intramuscular), usually as a small daily or several-times-weekly dose from a compounded vial. The promise is that skipping the gut and the IV chair gives you the "benefits of a drip" in a self-administered shot. Whether that promise holds is exactly what the evidence has to settle.

The core problem: there are no outcome trials of injected NAD+

Stated as plainly as possible: **there is no rigorous randomized controlled trial showing that subcutaneous or intramuscular NAD+ improves energy, focus, recovery, or any aging-related outcome in humans.** Not a single published outcome RCT exists for the injectable route. That isn't a hostile framing — it's simply where the literature stands.

The closest human data on putting NAD+ *directly* into the body (rather than swallowing a precursor) comes from a single 2019 pilot of **intravenous** NAD+, which tracked the plasma and urine NAD+ metabolome during a 6-hour infusion ³. Even there, free NAD+ was largely undetectable in blood for hours as the body metabolized it — and the study measured biochemistry, not whether anyone felt or performed better. There is no comparable pharmacokinetic study for subcutaneous or IM NAD+ at all, let alone a clinical-outcome trial. So when a clinic markets injections as "proven," that claim is not anchored to a trial of injections.

The better-studied path: oral NMN and NR precursors

To see what raising NAD+ can — and can't — realistically do, you have to look at the route that actually has trials: **oral precursors**, nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). This is the crucial distinction the injection marketing blurs.

Oral precursors clearly hit the biochemical target. NR's pharmacokinetics in humans are well characterized — it raises blood NAD+ predictably and dose-dependently ⁴. Oral NMN reliably raises blood NAD+ and is well tolerated in a dose-ranging RCT ⁵; a pharmaceutical-grade NMN formulation cleanly increased circulating NAD+ and its metabolome ⁶; and chronic NR elevates NAD+ in healthy middle-aged and older adults ⁷. So the *precursors* unambiguously move the biomarker.

But — and this is the part that matters most — raising the biomarker has repeatedly failed to translate into felt benefit. When NR augmented the aged human muscle NAD+ metabolome, it did **not** improve muscle bioenergetics or physical performance ⁸. When NR raised blood NAD+ in older adults with mild cognitive impairment, neurocognitive scores were unchanged ⁹. A systematic review and meta-analysis found the metabolic benefits of NAD+ precursors limited and inconsistent despite reliably raised NAD+ ¹⁰. The clearest positive human signal is narrow: a randomized crossover study found oral NMN improved muscle insulin sensitivity in prediabetic women ¹¹ — a specific metabolic endpoint in a specific population, not a general energy or anti-aging result. And much of the most exciting "rejuvenation" data is from mice, where long-term NMN mitigated age-associated physiological decline ¹² — striking, but not a human outcome.

The logic here is hard to escape: if the *oral* precursors — the ones with real RCTs — struggle to convert higher NAD+ into how people feel, an injectable route with **zero** outcome trials cannot honestly claim to do better. We walk through the precursor evidence in depth in our NAD+ therapy evidence pillar and compare the two precursors head-to-head in NMN vs NR.

Injections vs IV vs oral: what each route can and can't claim

It helps to line the routes up honestly:

- **Oral NMN / NR.** The only route with a real human trial base. Reliably raises NAD+ ⁴⁵⁷; benefits on energy, cognition, and metabolism are modest, mixed, or null ⁸⁹¹⁰, with one narrow positive insulin-sensitivity signal ¹¹. Cheapest by far. - **IV NAD+.** Heavily marketed; one human pharmacokinetic pilot, no outcome RCTs ³. Expensive and time-consuming. See our NAD+ IV therapy evidence and cost guide. - **Subcutaneous / IM injections.** No human pharmacokinetic study and no outcome RCT specific to the route. Positioned as a cheaper, at-home alternative to IV, but its evidence base is thinner than IV's, not stronger.

The marketing instinct is to treat these as interchangeable — "it's all NAD+." Pharmacologically the route matters enormously, and on evidence the injectable route is the *least* studied of the three, not a validated shortcut. The same gap applies to the "instant energy" claims attached to shots; we break those down in does NAD+ boost energy.

Side effects and safety

The most reliable, well-documented effect of parenteral NAD+ is, ironically, its side effects during administration. In the IV pilot, infusing NAD+ too quickly provoked chest tightness or pressure, flushing, nausea, cramping, and lightheadedness — which is precisely why the infusion was stretched over hours ³. Subcutaneous and IM injections are typically smaller per-dose, but users commonly report injection-site reactions, flushing, and a transient "rushing" or nauseated feeling — consistent with the same dose-rate sensitivity.

On longer-term safety, what reassurance exists again comes from the **oral** literature: a dedicated trial of high-dose NR (NR-SAFE) found it generally safe and well tolerated ¹³, and tolerability has been consistent across the oral NMN and NR trials. But "safe in oral trials" does not transfer automatically to repeated injection of NAD+, which has not been studied for long-term safety. Because injectable NAD+ in the US is **compounded** (it is not an FDA-approved finished drug), product quality, sterility, and dosing accuracy depend on the compounding pharmacy — so clinical oversight and a reputable source matter. Anyone who is pregnant, has a medical condition, or takes other medications should clear it with a clinician first; this is consumer education, not medical advice.

What NAD+ injections typically cost

Injections are marketed partly on cost — cheaper than an IV drip — but they are not cheap relative to the route that actually has evidence. Pricing is set entirely by clinics and telehealth services; there is no insurance coverage, because injectable NAD+ is not an approved treatment for any condition.

Typical real-world US pricing looks roughly like this:

- **Compounded subcutaneous/IM NAD+ vials** via telehealth commonly run about **$150–$400+ per month**, depending on dose and program, often bundled with a provider consult fee. - **In-clinic injection visits** are usually priced per shot and add up similarly or more over a month. - That still undercuts **IV NAD+** (often **$300–$1,000+ per single infusion**, with multi-session protocols reaching the low thousands), which is the comparison clinics lean on.

But the honest comparison isn't injection-vs-IV — it's injection-vs-evidence. **Oral NMN or NR**, the routes with actual human trials showing they raise NAD+, typically cost a fraction of an injection program per month. So with injections you're paying a premium for an *unproven* delivery method, not for better-proven results.

The bottom line

NAD+ injections are a compounded, clinic- and telehealth-marketed product whose promotion far outruns its evidence. There are **no** randomized controlled trials — and not even a human pharmacokinetic study — showing that subcutaneous or intramuscular NAD+ improves energy, focus, recovery, or aging. The only human data on delivering NAD+ directly is a single IV pharmacokinetic pilot that measured biochemistry, not outcomes ³. The credible evidence that NAD+ can be raised at all comes from inexpensive **oral** precursors — and even those reliably move the biomarker without reliably improving how people feel or function ⁸⁹¹⁰.

If you're drawn to NAD+, the evidence-based move is to understand the whole picture before paying for a shot. Start with our NAD+ therapy evidence pillar, compare the precursors in NMN vs NR, see how the IV route really stacks up in our NAD+ IV therapy guide, and check how products and providers compare on our NAD+ rankings hub. Treat injectable NAD+ as an expensive, unproven option — not the proven shortcut it's sold as.